Peptide Comparison
DihexavsNoopept (Omberacetam)
Angiotensin IV-derived oligopeptide that potentiates hepatocyte growth factor to drive synaptogenesis and cognitive enhancement with extraordinary potency
Ultra-potent dipeptide nootropic and prodrug of cycloprolylglycine that enhances cognition through BDNF/NGF upregulation, AMPA receptor modulation, and multicomponent neuroprotection at doses 1000 times lower than piracetam
At a Glance
Quick
comparison
Dose Range
Dihexa
5–20 mg
Noopept (Omberacetam)
10–30 mg
Frequency
Dihexa
Once daily
Noopept (Omberacetam)
Multiple times daily
Administration
Dihexa
Oral (capsule/tablet)
Noopept (Omberacetam)
Oral (tablet/capsule)
Cycle Length
Dihexa
4-6 weeks
Noopept (Omberacetam)
12+ weeks
Onset Speed
Dihexa
Moderate (1-2 weeks)
Noopept (Omberacetam)
Rapid (hours to days)
Evidence Level
Dihexa
Strong human trials (Phase 3 or FDA approved)
Noopept (Omberacetam)
Limited human trials
Efficacy
Benefit
ratings
Cognitive
Healing & Recovery
Anti-Aging
Technical Data
Compound
specifications
Dihexa
Molecular Formula
C27H44N4O5
Molecular Weight
504.7 g/mol
Half-Life
~12 days (following IV administration in rats)
Bioavailability
Orally active and blood-brain barrier permeable — specific oral bioavailability percentage not published
CAS Number
1401708-83-5
Noopept (Omberacetam)
Molecular Formula
C17H22N2O4
Molecular Weight
318.4 g/mol
Half-Life
Short plasma half-life (minutes); rapidly converted to active metabolite cycloprolylglycine which has a longer pharmacological duration; effects persist for hours after dosing
Bioavailability
Orally bioavailable with BBB penetration; metabolized to active cycloprolylglycine; approximately 1000-fold more potent than parent compound piracetam
CAS Number
157115-85-0
Protocols
Dosing
tiers
Dihexa
Noopept (Omberacetam)
Applications
Best
suited for
Dihexa
Age-Related Cognitive Decline
Dihexa directly addresses the synaptic loss that underlies age-related cognitive decline by building new functional synaptic connections in the hippocampus. Animal studies demonstrate restored spatial learning in aged rats, making it a compelling candidate for combating memory loss associated with aging.
Neuroplasticity Enhancement
Unlike nootropics that work through neurotransmitter modulation, dihexa drives physical neuroplasticity — the formation of new dendritic spines and synapses. This makes it ideal for individuals looking to enhance their brain's capacity for learning and adaptation at a structural level.
Neurodegenerative Disease Research
Preclinical evidence in APP/PS1 Alzheimer's mice and scopolamine-induced amnesia models positions dihexa as a leading research compound for neurodegenerative disease. It is patented for potential use in Alzheimer's and Parkinson's diseases, with ongoing interest from the research community.
Advanced Nootropic Stacking
Dihexa's unique mechanism (HGF/c-Met potentiation) is complementary to most other nootropic mechanisms, making it an excellent addition to advanced cognitive enhancement protocols when combined with choline donors, racetams, or adaptogens.
Noopept (Omberacetam)
Cognitive enhancement for learning, memory formation, and information retrieval
Noopept (Omberacetam) is particularly well-suited for individuals focused on cognitive enhancement for learning, memory formation, and information retrieval. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Neuroprotection against oxidative stress and age-related cognitive decline
Noopept (Omberacetam) is particularly well-suited for individuals focused on neuroprotection against oxidative stress and age-related cognitive decline. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms
Noopept (Omberacetam) is particularly well-suited for individuals focused on nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Support during periods of intense intellectual work or study
Noopept (Omberacetam) is particularly well-suited for individuals focused on support during periods of intense intellectual work or study. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Dihexa
Common
- Headache
- Vivid dreams or altered sleep patterns
- Emotional sensitivity
- Mild fatigue during adjustment
Uncommon
- Gastrointestinal discomfort
Serious
- Theoretical oncogenic risk from c-Met activation
Noopept (Omberacetam)
Common
- Headache
- Irritability or restlessness
- Sleep disturbance
- Mild gastrointestinal discomfort
- Vivid dreams
Uncommon
- Blood pressure increase
Serious
- Allergic reaction
Research Status
Safety
& evidence
Dihexa
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
Dihexa has demonstrated a favorable safety profile in published animal studies, with no reported tumorigenic effects or organ toxicity at cognitive-enhancing doses. However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist. The primary theoretical safety concern is sustained activation of the HGF/c-Met proto-oncogenic pathway, which could theoretically promote tumor initiation or growth. The extremely long half-life (~12 days) raises additional concerns about compound accumulation with chronic daily dosing. Anecdotal reports from the nootropics community generally describe good tolerability at doses of 5-20 mg daily, with headaches and vivid dreams as the most commonly reported effects.
Contraindications
- xKnown or suspected malignancy — c-Met/HGF pathway activation may promote tumor growth
- xPregnancy and breastfeeding — no safety data available
- xHistory of cancer, particularly HGF/c-Met-driven tumors (hepatocellular, gastric, lung)
- xSevere hepatic impairment
Noopept (Omberacetam)
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Noopept demonstrates excellent safety in Russian clinical trials with LD50 >2000 mg/kg (oral, rats)—approximately 100 times higher than therapeutic doses. No serious adverse events reported in human studies up to 30 mg/day for 6-12 weeks. Mild side effects (headache, irritability) occur in <5% of users and resolve with dose reduction. No carcinogenicity, mutagenicity, or teratogenicity in preclinical testing; minimal drug interactions due to lack of hepatic CYP450 metabolism.
Contraindications
- xKnown hypersensitivity to Noopept, piracetam, or other racetam-class compounds
- xPregnancy and breastfeeding — insufficient safety data
- xSevere hepatic impairment — Noopept undergoes hepatic metabolism
- xSevere renal impairment — metabolites are renally excreted
- xLactose intolerance (some tablet formulations contain lactose as excipient)
Decision Guide
Which is
right for you?
Choose Dihexa if...
- Cognitive enhancement and memory consolidation in age-related decline
- Supporting neuroplasticity and new synaptic connection formation
- Research into neurodegenerative disease therapeutics (Alzheimer's, Parkinson's)
- Nootropic stacking for individuals seeking enhanced learning capacity
Choose Noopept (Omberacetam) if...
- Cognitive enhancement for learning, memory formation, and information retrieval
- Neuroprotection against oxidative stress and age-related cognitive decline
- Nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms
- Support during periods of intense intellectual work or study